Autoantibodies to the islet cell antigen SOX‐13 are associated with duration but not type of diabetes
Timothy M. E. Davis(Liberty University), Rury R. Holman(University of Oxford), M. J. Rowley(The University of Western Australia), C A Cull(Churchill Hospital), Z Mehta(University of Oxford), David Bruce(United States Department of Energy), S. Fida(The University of Western Australia), I. R. Mackay(The University of Western Australia)
Cited by 10
Related Papers
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k